

Martin G Sanda

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11093713/martin-g-sanda-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

15,442
citations

53
h-index

124
g-index

173
ext. papers

17,500
ext. citations

5.3
avg, IF

5.82
L-index

#	Paper	IF	Citations
162	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , 2002 , 419, 624-9	30.4	2085
161	Quality of life and satisfaction with outcome among prostate-cancer survivors. <i>New England Journal of Medicine</i> , 2008 , 358, 1250-61	59.2	1697
160	Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. <i>Urology</i> , 2000 , 56, 899-905	1.6	1127
159	Autoantibody signatures in prostate cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1224-35	59.2	521
158	alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 1662-70	27.4	489
157	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. <i>Journal of Urology</i> , 2018 , 199, 683-690	2.5	393
156	A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. <i>Journal of Urology</i> , 2011 , 185, 1650-5	2.5	322
155	Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 557-66	2.2	318
154	Contemporary Diagnosis and Management of Renal Angiomyolipoma. <i>Journal of Urology</i> , 2002 , 168, 1315-1325	2.5	316
153	Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2772-80	2.2	299
152	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. <i>Science Translational Medicine</i> , 2011 , 3, 94ra72	17.5	281
151	Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. <i>Urology</i> , 2010 , 76, 1245-50	1.6	258
150	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. <i>Nature</i> , 2019 , 576, 465-470	50.4	237
149	The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1497-509	4	230
148	Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 661-8	9.7	220
147	Prediction of erectile function following treatment for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 1205-14	27.4	213
146	Demonstration of a rational strategy for human prostate cancer gene therapy. <i>Journal of Urology</i> , 1994 , 151, 622-8	2.5	204

145	Can urinary PCA3 supplement PSA in the early detection of prostate cancer?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4066-72	2.2	186
144	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. <i>Journal of Urology</i> , 2018 , 199, 990-997	2.5	183
143	Molecular characterization of defective antigen processing in human prostate cancer. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 280-5	9.7	182
142	Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. <i>Clinical Cancer Research</i> , 2009 , 15, 4706-11	12.9	181
141	Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. <i>Urology</i> , 1999 , 53, 260-6	1.6	175
140	The prostate health index selectively identifies clinically significant prostate cancer. <i>Journal of Urology</i> , 2015 , 193, 1163-9	2.5	171
139	Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3705-15	2.2	169
138	Daily prostate targeting using implanted radiopaque markers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 699-703	4	168
137	Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 9887-92	11.5	166
136	A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1193-200	4	165
135	Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. <i>Urology</i> , 2015 , 85, 101-5	1.6	161
134	Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. <i>Urology</i> , 1995 , 45, 831-8	1.6	161
133	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 566-71	2.8	160
132	Living with prostate cancer: patients and spouses psychosocial status and quality of life. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4171-7	2.2	160
131	Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. <i>Urology</i> , 2014 , 83, 1362-7	1.6	155
130	Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 5794-802	12.9	130
129	Racial/ethnic disparities in the treatment of localized/regional prostate cancer. <i>Journal of Urology</i> , 2004 , 171, 1504-7	2.5	123
128	Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. <i>Clinical Cancer Research</i> , 2013 , 19, 2442-50	12.9	117

127	The role of metastasis-associated protein 1 in prostate cancer progression. <i>Cancer Research</i> , 2004 , 64, 825-9	10.1	116
126	Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 834-43	9.7	113
125	Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. <i>Journal of Urology</i> , 2015 , 194, 65-72	2.5	110
124	Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. <i>Journal of Urology</i> , 2011 , 186, 865-72	2.5	107
123	Longitudinal analysis of a model to predict quality of life in prostate cancer patients and their spouses. <i>Annals of Behavioral Medicine</i> , 2008 , 36, 117-28	4.5	106
122	Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. <i>Journal of Urology</i> , 2003 , 169, 1453-7	2.5	97
121	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. <i>Journal of Urology</i> , 2016 , 195, 313-20	2.5	93
120	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017 , 3, 1085-1093	13.4	88
119	Genetic susceptibility of benign prostatic hyperplasia. <i>Journal of Urology</i> , 1994 , 152, 115-9	2.5	86
118	[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. <i>Journal of Urology</i> , 2008 , 180, 539-43; discussion 543	2.5	82
117	Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	72
116	Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. <i>Urology</i> , 2006 , 68, 166-71	1.6	72
115	Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. <i>Cancer</i> , 2013 , 119, 1729-35	6.4	71
114	Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4980-5	2.2	68
113	Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. <i>Cancer</i> , 2014 , 120, 1076-82	6.4	65
112	Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. <i>American Journal of Pathology</i> , 2004 , 164, 787-93	5.8	62
111	Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study. <i>Urology</i> , 2010 , 75, 1004-8	1.6	60
110	Early castration reduces prostatic carcinogenesis in transgenic mice. <i>Urology</i> , 1999 , 54, 1112-9	1.6	55

109	Concordance rates for benign prostatic disease among twins suggest hereditary influence. <i>Urology</i> , 1994 , 44, 646-50	1.6	52
108	Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with Galactosylceramide. <i>PLoS ONE</i> , 2010 , 5, e11311	3.7	49
107	Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. <i>Journal of Urology</i> , 2009 , 182, 2653-8	2.5	48
106	Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. <i>Urology</i> , 2006 , 68, 1224-9	1.6	48
105	Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. <i>Cancer Research</i> , 2005 , 65, 4126-33	10.1	47
104	Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. <i>Radiotherapy and Oncology</i> , 2015 , 116, 179-84	5.3	46
103	LONGITUDINAL COHORT ANALYSIS OF LETHAL PROSTATE CANCER PROGRESSION IN TRANSGENIC MICE. <i>Journal of Urology</i> , 1998 , 160, 1500-1505	2.5	46
102	Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. <i>Urology</i> , 2000 , 55, 904-8	1.6	46
101	Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. <i>Journal of Urology</i> , 2014 , 191, 638-45	2.5	43
100	Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. <i>Urology</i> , 2002 , 59, 480-4	1.6	43
99	Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. <i>Journal of Clinical Investigation</i> , 2002 , 110, 351-60	15.9	42
98	Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. <i>Prostate</i> , 2001 , 47, 194-204	2.4	38
97	Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. <i>Urology</i> , 2002 , 59, 740-5; discussion 745-6	1.6	38
96	Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer. <i>Cancer</i> , 2011 , 117, 4651-8	6.4	35
95	Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer. <i>Urology</i> , 2002 , 60, 276-80	1.6	35
94	Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2014 , 110, 291-7	5.3	34
93	Tracking humoral responses using self assembling protein microarrays. <i>Proteomics - Clinical Applications</i> , 2008 , 2, 1518-27	3.1	34
92	Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. <i>Prostate</i> , 2008 , 68, 1517-30	4.2	34

91	PartnersQong-term appraisal of their caregiving experience, marital satisfaction, sexual satisfaction, and quality of life 2 years after prostate cancer treatment. <i>Cancer Nursing</i> , 2013 , 36, 104-13 ^{2.6}	32
90	Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling. <i>Urology</i> , 2004 , 64, 117-22	1.6 32
89	Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. <i>Urology</i> , 2018 , 117, 57-63	1.6 30
88	Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. <i>Seminars in Radiation Oncology</i> , 2008 , 18, 67-72	5.5 30
87	Clinical and Biological Characteristics of Familial Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1997 , 157, 876-879	2.5 29
86	Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 511-520	4 28
85	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. <i>Current Opinion in Immunology</i> , 2015 , 35, 15-22	7.8 27
84	The experiences of unpartnered men with prostate cancer: a qualitative analysis. <i>Journal of Cancer Survivorship</i> , 2011 , 5, 132-41	5.1 27
83	Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery. <i>Quality of Life Research</i> , 2008 , 17, 915-26	3.7 27
82	Use of quality indicators to evaluate the care of patients with localized prostate carcinoma. <i>Cancer</i> , 2003 , 97, 1428-35	6.4 26
81	Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4521-4521	2.2 26
80	Survivorship after prostate cancer treatment: spousesQquality of life at 36 months. <i>Oncology Nursing Forum</i> , 2013 , 40, 567-73	1.7 25
79	Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004 , 22, 20-4	2.8 25
78	Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. <i>Journal of Urology</i> , 2006 , 176, 257-61; discussion 261-2	2.5 23
77	Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. <i>Human Pathology</i> , 2014 , 45, 2136-43	3.7 22
76	Updating risk prediction tools: a case study in prostate cancer. <i>Biometrical Journal</i> , 2012 , 54, 127-42	1.5 22
75	Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial. <i>Journal of Urology</i> , 2018 , 199, 89-97	2.5 22
74	Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine. <i>Prostate</i> , 2017 , 77, 990-999	4.2 21

73	Usability evaluation and adaptation of the e-health Personal Patient Profile-Prostate decision aid for Spanish-speaking Latino men. <i>BMC Medical Informatics and Decision Making</i> , 2015 , 15, 56	3.6	20
72	Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. <i>Prostate</i> , 2010 , 70, 1002-11	4.2	20
71	Histopathologic characterization of hereditary benign prostatic hyperplasia. <i>Urology</i> , 1996 , 48, 650-3	1.6	20
70	Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer. <i>Current Urology Reports</i> , 2004 , 5, 212-9	2.9	19
69	Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2017 , 197, 109-114	2.5	18
68	Satisfaction with information used to choose prostate cancer treatment. <i>Journal of Urology</i> , 2014 , 191, 1265-71	2.5	18
67	Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 213-8	2.8	18
66	External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 304-317	4	17
65	A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. <i>BJU International</i> , 2019 , 124, 609	5.6	17
64	epiCaPtore: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer. <i>JCO Precision Oncology</i> , 2019 , 2019,	3.6	17
63	Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. <i>Urology</i> , 2016 , 91, 143-9	1.6	17
62	Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. <i>Urology</i> , 2013 , 82, 1363-8	1.6	17
61	Watchful waiting and quality of life among prostate cancer survivors in the PhysiciansQHealth Study. <i>Journal of Urology</i> , 2011 , 186, 1862-7	2.5	17
60	A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 2141-51	27.4	17
59	Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3042-3050	2.2	17
58	Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial. <i>Cancer</i> , 2012 , 118, 2651-8	6.4	16
57	Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. <i>Urology</i> , 2004 , 63, 946-50	1.6	16
56	Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. <i>Prostate</i> , 2019 , 79, 961-968	4.2	15

55	RNA biomarkers to facilitate the identification of aggressive prostate cancer. <i>Molecular Aspects of Medicine</i> , 2015 , 45, 37-46	16.7	15
54	Comparison of validated instruments measuring sexual function in men. <i>Urology</i> , 2010 , 76, 380-6	1.6	15
53	Gene therapy for human prostate cancer. Translational research in the hormone refractory Dunning prostate cancer model. <i>Cancer</i> , 1995 , 75, 2013-2020	6.4	15
52	Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. <i>BJU International</i> , 2013 , 111, E84-91	5.6	14
51	MAXIMUM TUMOR DIMENSION PROVIDES A CLINICALLY USEFUL AND INDEPENDENTLY SIGNIFICANT MEASURE FOR PREDICTING PSA-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1999 , 241	2.5	14
50	Evaluation of patient-reported quality-of-life outcomes after renal surgery. <i>Urology</i> , 2012 , 79, 1268-73	1.6	12
49	The role of the transcription factor SIM2 in prostate cancer. <i>PLoS ONE</i> , 2011 , 6, e28837	3.7	12
48	Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. <i>PLoS ONE</i> , 2014 , 9, e93231	3.7	11
47	Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. <i>European Urology Focus</i> , 2019 , 5, 54-61	5.1	11
46	Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. <i>Journal of Urology</i> , 2017 , 197, 376-384	2.5	10
45	Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. <i>Prostate</i> , 2002 , 53, 183-91	4.2	8
44	Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e265-73	3.3	8
43	Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. <i>World Journal of Urology</i> , 2000 , 18, 136-42	4	7
42	Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 770-777	4	7
41	Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, e117-25	3.3	6
40	Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. <i>BJU International</i> , 2017 , 119, 961-967	5.6	5
39	Prostate Cancer Biomarker Development: National Cancer Institute Early Detection Research Network Prostate Cancer Collaborative Group Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2454-2462	4	5
38	A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. <i>Theranostics</i> , 2021 , 11, 6214-6224	12.1	5

37	Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis. <i>BMC Medical Informatics and Decision Making</i> , 2019 , 19, 6	3.6	4
36	Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. <i>Urology</i> , 2019 , 127, 53-60	1.6	4
35	The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells. <i>BMC Cancer</i> , 2015 , 15, 604	4.8	4
34	Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1357-65	7.4	4
33	Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 32-37	3.3	4
32	Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 181.e15-181.e21	2.8	4
31	A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. <i>Asian Journal of Urology</i> , 2020 , 7, 161-169	2.7	4
30	In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal US-guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. <i>Radiology Imaging Cancer</i> , 2020 , 2, e190078	1.4	3
29	In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? A pilot test-retest reliability study. <i>British Journal of Radiology</i> , 2018 , 91, 20170603	3.4	3
28	Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy. <i>Prostate</i> , 2008 , 68, 715-27	4.2	3
27	Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e494-e504	3.3	2
26	Urinary obstructive problems exposed but hormonal health-related quality-of-life concerns eschewed in prostate cancer quality-of-life study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4667-8	2.2	2
25	Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4. <i>Nature Reviews Urology</i> , 2009 , 6, 124-5	5.5	2
24	Nomogram predicting treatment-related sexual dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 51-51	2.2	2
23	Evaluating Clinical Implementation Approaches for Prostate Cancer Decision Support. <i>Urology Practice</i> , 2019 , 6, 93-99	0.8	2
22	Clinical and Biological Characteristics of Familial Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1997 , 876-879	2.5	2
21	Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. <i>Cancer</i> , 2021 , 127, 2974-2979	6.4	2
20	Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 493.e9-493.e15	2.8	2

19	Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro. <i>Journal of Urology</i> , 2017 , 198, 997-999	2.5	1
18	Quality of life after prostate cancer treatment. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3038; author reply 3038-9	2.2	1
17	A safety-modified SV40 Tag developed for human cancer immunotherapy. <i>Drug Design, Development and Therapy</i> , 2009 , 2, 17-24	4.4	1
16	Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.. <i>Human Genetics and Genomics Advances</i> , 2022 , 3, 100070-100070	0.8	1
15	Genitourinary Prosthetic Use among Prostate Cancer Survivors Treated with Radical Prostatectomy. <i>Urology Practice</i> , 2019 , 6, 123-128	0.8	1
14	In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. <i>Radiology Imaging Cancer</i> , 2019 , 1, e190016	1.4	1
13	Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. <i>Practical Radiation Oncology</i> , 2018 , 8, 445-451	2.8	1
12	Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. <i>Journal of Urology</i> , 2022 , 207, 127-136	2.5	1
11	Live longer but not better...yet. <i>Lancet Oncology, The</i> , 2009 , 10, 313-4	21.7	0
10	Editorial comment. Nerve sparing during radical prostatectomy is associated with better recovery of urinary continence. <i>Urology</i> , 2009 , 73, 1340-1; author reply 1341	1.6	
9	A Branched DNA Assay for Detecting TMPRSS2-ERG Fusions. <i>Urology</i> , 2009 , 74, 1162	1.6	
8	Is androgen suppression therapy associated with early onset of fatal myocardial infarction?. <i>Nature Reviews Urology</i> , 2008 , 5, 184-5		
7	Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early-stage prostate cancer. <i>Current Prostate Reports</i> , 2004 , 2, 109-116		
6	Clinical Implications of Measuring Quality-of-Life in Early Stage Prostate Cancer 2012 , 297-317		
5	Nomogram predicting treatment-related bowel dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 55-55	2.2	
4	Nomogram predicting treatment-related urinary incontinence for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), or brachytherapy (PI).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 49-49	2.2	
3	Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 88-88	2.2	
2	Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 84-84	2.2	

- 1 Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 40, 58.e9-58.e9 2.8